APA (7th ed.) Citation

F, S., S, B., P, G. R., A, P., X, L., P, M., . . . T, F. (2021). Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. American journal of hematology, 96(11), E423. https://doi.org/10.1002/ajh.26319

Chicago Style (17th ed.) Citation

F, Schjesvold, et al. "Isatuximab Plus Pomalidomide and Dexamethasone in Frail Patients with Relapsed/refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis." American Journal of Hematology 96, no. 11 (2021): E423. https://doi.org/10.1002/ajh.26319.

MLA (9th ed.) Citation

F, Schjesvold, et al. "Isatuximab Plus Pomalidomide and Dexamethasone in Frail Patients with Relapsed/refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis." American Journal of Hematology, vol. 96, no. 11, 2021, p. E423, https://doi.org/10.1002/ajh.26319.